Instructions to Authors
23 December 2020
Cover Image
23 December 2020
2020 Hepatology Referees (Volumes 71 and 72)
23 December 2020
REPLY:
Lung‐Yi Mak, Man‐Fung Yuen – 23 December 2020
Hepatology Highlights
Adam Buckholz, Robert S. Brown, Hirsh Trivedi, Muzammil M. Khan, Hira Hanif, Daryl T.Y. Lau, Amneet Hans, Giorgio Roccaro, Joseph F. Pisa, Nidhi Jalan‐Sakrikar, Robert E. Schwartz, Nicholas W. Russo, Tejasav S. Sehrawat, Enis Kostallari, Adebowale O. Bamidele, Gopanandan Parthasarathy – 23 December 2020
Table of contents
23 December 2020
Correction
23 December 2020
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
Bertus Eksteen, Christopher L. Bowlus, Aldo J. Montano‐Loza, Eric Lefebvre, Laurent Fischer, Pamela Vig, Eduardo Bruno Martins, Jawad Ahmad, Kidist K. Yimam, Paul J. Pockros, Jordan J. Feld, Gerald Minuk, Cynthia Levy – 22 December 2020 – Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C‐C chemokine receptor types 2 and 5 (CCR2/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC.
Portal Vein Complications After Adult Living Donor Liver Transplantation: Time of Onset and Deformity Patterns Affect Long‐Term Outcomes
Yuzuru Sambommatsu, Keita Shimata, Sho Ibuki, Yasuko Narita, Kaori Isono, Masaki Honda, Tomoaki Irie, Masashi Kadohisa, Seiichi Kawabata, Hidekazu Yamamoto, Yasuhiko Sugawara, Osamu Ikeda, Yukihiro Inomata, Taizo Hibi – 21 December 2020 – Portal vein complications (PVCs) after adult living donor liver transplantation (LDLT) are potentially lethal.
Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center
Sarah A. Rojas, Job G. Godino, Adam Northrup, Maureen Khasira, Aaron Tam, Lisa Asmus, Catherine Frenette, Christian B. Ramers – 21 December 2020 – Hepatitis C virus (HCV) is a major cause of cirrhosis, liver cancer, and mortality in the United States. We assessed the effectiveness of decentralized HCV treatment delivered by nurse practitioners (NPs), primary care physicians (PMDs), or an infectious disease physician (ID MD) using direct‐acting antivirals in a Federally Qualified Health Center (FQHC) in urban San Diego, CA.